An experimental drug targeting triple-negative breast cancer overwhelms cancer cells with toxic fats, according to new tests on human-derived tumors in mice. Triple-negative breast cancer lacks three common drug targets, making it one of the most aggressive forms of the disease.

The compound, known as DH20931, appears to push cancer cells past their limits by triggering a surge in fat-like molecules called ceramides.

Researchers led by Henry Daniell of the School of Dental Medicine have shown that extracts from bioengineered chewing gum reduce the levels of three microbes known to be associated with head and neck squamous cell cancer (HNSCC), paving the way for more effective and affordable therapies. Their findings are published in Scientific Reports.

Millions of Americans are still battling potentially deadly hepatitis C even though they could be cured with antiviral drugs they are not receiving, a new analysis reveals.

University of Virginia School of Medicine researcher Sanjay Kishore, MD, and colleagues at Mass General Brigham looked at prescribing trends for the drugs, known as direct-acting antivirals. They found that prescriptions rose rapidly when the drugs were first introduced in 2013, then peaked in 2015.

Macrophages, key regulators of tissue health and immune defense, are among the most abundant immune cells in solid tumors. Their role in cancer has been difficult to define because even closely related macrophage populations can have very different, and sometimes opposing, functions.

Funded by the National Institutes of Health’s National Heart, Lung, and Blood Institute, researchers at Geisel School of Medicine, led by principal investigator Claudia Jakubzick, PhD, professor of microbiology and immunology,

Researchers at Linköping University show how two important cancer-related proteins can be prevented from collaborating with each other. The discovery shows the way towards future medications to combat e.g. neuroblastoma in children. Their study has been published in the journal Nature Communications.

“Today we can cure many cases of childhood cancer that were incurable ten years ago. But there’s still an important group of childhood tumours that evade cure.

A three-dimensional experimental system has been developed to study the response to drugs in low-grade glioma, a tumor of the central nervous system that often occurs in children. The project, developed by the University of Trento, Bambino Gesù Children's Hospital and Sapienza University of Rome, is a breakthrough in the study, understanding and treatment of the disease.

A new study finds that combining the current medications for Alzheimer’s disease with small molecules derived from micronutrients found in grapes, berries, peanuts and turmeric is a safer and more effective way to treat the disease.

Individuals with Alzheimer’s have a buildup of toxic amyloid proteins in the brain. Researchers from the School of Pharmacy at the University of Waterloo combined amyloid-destroying small molecules with anti-amyloid antibodies that are already used in Alzheimer’s treatment.

Scientists at the Buck Institute for Research on Aging have shown that an orally administered small molecule, N-propargylglycine (N-PPG), can completely prevent the formation of calcium oxalate kidney stones, protect against kidney failure, and fully restore normal survival in a mouse model of Primary Hyperoxaluria Type 2 (PH2), a rare and currently untreatable genetic disorder that causes progressive kidney failure in infants and young adults.

Fans of Korean skincare may be familiar with ‘hero ingredient’ Madecassic acid for its skin-soothing properties, but researchers at the University of Kent have revealed its greater potential for use in the battle against antibiotic resistance.

Using a combination of computational screening and laboratory experiments, scientists in the School of Natural Sciences together with those at University College London (UCL) have demonstrated how this natural chemical from the common Asian herb Centella asiatica, is an effective antibacterial drug.

Bristol Myers Squibb (NYSE: BMY), a global leader in oncology, announced the evolution of Standing in the Gaap, a long-running program designed to help address persistent gaps in care for people living with multiple myeloma (MM) in medically underserved communities. Building on a decade of sustained commitment, BMS is reinforcing its focus on equitable access to multiple myeloma education, resources, and community-driven solutions by expanding the program to reach more patients and care partners.

University of Virginia School of Medicine scientists have developed a bold new approach to drug development and discovery that could dramatically accelerate the creation of new medicines.

UVA’s Nikolay V. Dokholyan, PhD, and colleagues have developed a suite of artificial intelligence-powered tools, called YuelDesign, YuelPocket and YuelBond, that work together to transform how new drugs are created.

Scripps Research scientists have developed a new class of drug compounds that reduce harmful inflammation while leaving the body’s ability to fight infections intact - a long-sought goal in treating autoimmune diseases. The compounds, called ENDOtollins, work by interrupting a “molecular handshake” between two proteins inside immune cells.

In a paper published in the Journal of Clinical Investigation, a research team at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health reports developing a therapeutic intranasal (nose-delivered) DNA vaccine against tuberculosis (TB) that fuses two genes with the goal of directing the immune system to fight drug-tolerant bacterial “persisters” that can survive prolonged antibiotic therapy and contribute to disease relapse.

A hormone that reverses obesity in mice appears to work by signaling to a brain region involved in metabolism and appetite regulation, the same area targeted by the popular GLP-1 drugs. The finding, from University of Oklahoma researchers, is published in Cell Reports.

The study provides valuable new insight into the naturally occurring hormone, called FGF21 (fibroblast growth factor 21), which is already involved in drug development.

Researchers at the National Institutes of Health (NIH) have identified a novel, highly potent opioid that shows potential as a therapy for both pain and opioid use disorder. In a study published in Nature, the team observed the new drug’s effect in laboratory animals. They showed that it has high pain-relieving effects without causing respiratory depression, tolerance or other indicators of potential for addiction in humans.

Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, announced the integration of Abbott's comprehensive Precision Oncology portfolio into OncoEMR®, Flatiron's cloud-based Electronic Medical Record (EMR) platform.

Researchers at Aarhus University have developed a microscopic DNA needle that can deliver molecules directly into cells - and, crucially, help make sure they remain active once they get there. That addresses a major problem in modern medicine: much of what enters a cell is quickly sealed off in tiny bubbles and put out of action before it ever reaches its target.

How can cancer cells be targeted without damaging healthy tissue? This is one of the major challenges facing oncology today. Using synthetic DNA strands, a team from the University of Geneva (UNIGE) has created a “smart” system that can recognise cancer cells with exceptional precision and release powerful drugs only where they are needed. Beyond cancer treatment, this research paves the way to “smart” medicines and programmable drug delivery.

A research team led by the Fisabio Foundation has demonstrated that dermcidin, an antimicrobial peptide produced constitutively by the human body, also exhibits antiviral activity against the influenza virus. The study also shows that people who do not develop flu-like symptoms have higher baseline levels of this molecule, which could be associated with lower susceptibility to infection.

The model organ for this research project is the best pediatric brain tumor model developed so far and can be used to test new drugs. The results of the project, conducted by the University of Trento with Bambino Gesù Children's Hospital in Rome, were published in the Nature Protocols.

In recent years, cancer research switched from the study of two-dimensional assays (cultures on plastic) to organoids, more complex systems that make it possible to work in a three-dimensional environment and that allow for a more realistic observation of the disease.